Payment overview · 2025
General Payments
$943.94
28 reported records · 9 companies
Healthcare provider profile · identity verified
John L Herzog, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · GREENVILLE, MS · NPI 1093734949
Verified facts
What the public records show
CMS Open Payments records show John L Herzog, MD received $943.94 in general payments during 2025 across 28 reported records.
Penumbra, Inc. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Verquvo.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Verquvo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $316.16 | 33.5% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$251.87 | 26.7% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $152.66 | 16.2% | 8 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $78.79 | 8.3% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $50.46 | 5.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.39 | 4.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.80 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.80 | 1.7% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $15.01 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $943.94 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $197.22 | 5 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $178.68 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $152.66 | 8 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $118.94 | 1 | 2025 |
Source payment records
|
|||||
| Technical Education MRI Normalized: technical education mri |
Device | Philips North America LLC | $61.54 | 3 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $57.58 | 1 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $50.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| Intrasight Mobile Normalized: intrasight mobile |
Device | Philips North America LLC | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $15.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 485 | 197 |
| Metoprolol Succinate | Metoprolol Succinate | 442 | 214 |
| Eliquis | Apixaban | 308 | 96 |
| Furosemide | Furosemide | 307 | 153 |
| Brilinta | Ticagrelor | 255 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 243 | 91 |
| Farxiga | Dapagliflozin Propanediol | 235 | 101 |
| Losartan Potassium | Losartan Potassium | 228 | 100 |
| Irbesartan | Irbesartan | 226 | 105 |
| Gabapentin | Gabapentin | 223 | 89 |
| Nifedipine Er | Nifedipine | 218 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 192 | 96 |
| Potassium Chloride | Potassium Chloride | 185 | 93 |
| Entresto | Sacubitril/Valsartan | 179 | 55 |
| Carvedilol | Carvedilol | 157 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 70 |
| Hydralazine Hcl | Hydralazine Hcl | 145 | 66 |
| Amiodarone Hcl | Amiodarone Hcl | 128 | 70 |
| Nitroglycerin | Nitroglycerin | 125 | 92 |
| Cilostazol | Cilostazol | 122 | 65 |
| Omeprazole | Omeprazole | 119 | 56 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 116 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 37 |
| Simvastatin | Simvastatin | 69 | 24 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 65 | 41 |
| Metolazone | Metolazone | 64 | 40 |
| Spironolactone | Spironolactone | 62 | 36 |
| Xarelto | Rivaroxaban | 61 | 20 |
| Allopurinol | Allopurinol | 58 | 22 |
| Clonidine Hcl | Clonidine Hcl | 55 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 28 |
| Digoxin | Digoxin | 48 | 17 |
| Lisinopril | Lisinopril | 46 | 21 |
| Famotidine | Famotidine | 45 | 24 |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 15 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 37 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Atenolol | Atenolol | 32 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | 12 |
| Metformin Hcl | Metformin Hcl | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | 12 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 23 |
| Haloperidol | Haloperidol | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | 11 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 22 | 22 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Verquvo | Vericiguat | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 17 | 12 |
| Azithromycin | Azithromycin | 15 | 12 |
| Colchicine | Colchicine | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $943.94 · 28 records | Penumbra, Inc. | ABRE, AREXVY, CAPVAXIVE, CDS - MCT/CEM Monitoring, GALLANT, HAWKONE, Indigo System, Intrasight Mobile, Kerendia, Penumbra System, SHINGRIX, SYMPLICITY G3, Technical Education MRI, Tyvaso, VERQUVO, XIENCE SKYPOINT | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Verquvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Merck Sharp & Dohme LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error